Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.33 |
| ▸ | ASPH | Q12797 | 2/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.33 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.33 |
| ▸ | BAD | Q92934 | 1/20 | 0.33 |
| ▸ | BCL2L10 | Q9HD36 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631875 | 1.00 | RET (0.34) | RETBCL2L1ASPHBCL2ADORA1 | |
| SCHEMBL630736 | 0.91 | BCL2L1 (0.31) | BCL2L1ASPHBCL2ADORA1MCL1 | |
| SCHEMBL630737 | 0.91 | BCL2L1 (0.31) | BCL2L1ASPHBCL2ADORA1MCL1 | |
| SCHEMBL14263344 | 0.83 | RET (0.32) | RETBCL2L1ASPHBCL2ADORA1 | |
| SCHEMBL630702 | 0.81 | BCL2L1 (0.36) | RETBCL2L1ASPHBCL2ADORA1 | |
| SCHEMBL630701 | 0.81 | BCL2L1 (0.36) | RETBCL2L1ASPHBCL2ADORA1 | |
| Obatoclax SCHEMBL631676 | 0.76 | RAB9A (0.41) | RETBCL2L1ASPHBCL2ADORA1 | |
| Obatoclax SCHEMBL29354696 | 0.76 | RAB9A (0.41) | RETBCL2L1ASPHBCL2ADORA1 | |
| Obatoclax SCHEMBL2751250 | 0.76 | RAB9A (0.41) | RETBCL2L1ASPHBCL2ADORA1 | |
| Obatoclax SCHEMBL29519876 | 0.76 | RAB9A (0.41) | RETBCL2L1ASPHBCL2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644363-B1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC (CA) | 2012-02-22 | — | — | EP | claimed |
| US-20080318903-A1 | METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | claimed |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | claimed |
| US-8420638-B2 | Triheterocyclic compounds and compositions thereof | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2013-04-16 | — | — | US | disclosed |
| US-8420638-B2 | Triheterocyclic compounds and compositions thereof | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2013-04-16 | — | — | US | disclosed |
| EP-1644363-B1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC (CA) | 2012-02-22 | — | — | EP | disclosed |
| US-20120004224-A1 | Triheterocyclic Compounds and Compositions Thereof | Gemin X Pharmaceuticals Canada Inc. (formerly Gemin X Biotechnologies Inc.) | 2012-01-05 | — | — | US | disclosed |
| US-20120004224-A1 | Triheterocyclic Compounds and Compositions Thereof | Gemin X Pharmaceuticals Canada Inc. (formerly Gemin X Biotechnologies Inc.) | 2012-01-05 | — | — | US | disclosed |
| US-7709477-B2 | Methods for treating cancer | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-20080318903-A1 | METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| US-7425553-B2 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-09-16 | — | — | US | disclosed |
| US-7425553-B2 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-09-16 | — | — | US | disclosed |
| US-20080051400-A1 | Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318903-A1 | METHODS FOR TREATING CANCER | HCCS, EIF2AK2, ZC3HAV1 | RET 1778/4885BCL2L1 662/4885ASPH 503/4885 |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | ZC3HAV1, HCCS, PCNA | RET 861/4885BCL2L1 709/4885ASPH 850/4885 |
| US-20080051400-A1 | Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound | MPL, THPO, TTPA | RET 3449/4885BCL2L1 2224/4885ASPH 165/4885 |
| US-20120004224-A1 | Triheterocyclic Compounds and Compositions Thereof | ZC3HAV1, HCCS, PCNA | RET 861/4885BCL2L1 709/4885ASPH 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.